2seventy’s SC-DARIC33 IND Cleared by the FDA for R/R Pediatric AML; 2seventy Q3 2021 Earnings Summary
On Wednesday, December 1, 2seventy bio released their Q3 2021 financial results and operational updates (press release) highlighting their launch as an independent company. Moreover, management announced that the FDA has accepted an IND for SC-DARIC33’s (CD33 CAR-T) Ph1 PLAT-08 trial in r/r pediatric AML. Below, Celltelligence provides insights on 2seventy’s launch, while commenting on potential competitors for 2seventy’s SC-DARIC33 and bbT369 (CD20 x CD79a CAR-T) programs.